Colicin Immunity Protein
From Proteopedia
Line 1: | Line 1: | ||
- | + | <StructureSection load='3gkl' size='500' frame='true' align='right' scene='3gkl/Al/1' > | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
'''Immunity proteins''' against [[Colicin]]s (EcCIP) are produced by ''E. coli'' alongside the relevant colicin protein (EcCol) to protect the cell from the cytotoxic domain of the colicin. Usually this involves binding to and blocking the active site of the domain, to prevent it from targeting the cells own mechanisms. | '''Immunity proteins''' against [[Colicin]]s (EcCIP) are produced by ''E. coli'' alongside the relevant colicin protein (EcCol) to protect the cell from the cytotoxic domain of the colicin. Usually this involves binding to and blocking the active site of the domain, to prevent it from targeting the cells own mechanisms. | ||
Line 44: | Line 22: | ||
{{Clear}} | {{Clear}} | ||
==Directed evolution and Colicin7/Immunity-proteins complexes<ref>PMID:19749752</ref>== | ==Directed evolution and Colicin7/Immunity-proteins complexes<ref>PMID:19749752</ref>== | ||
- | + | ||
Iterative rounds of random mutagenesis and selection of <span style="color:yellow;background-color:black;font-weight:bold;">immunity protein 9 (colored yellow)</span> toward higher affinity for ColE7, and selectivity (against ColE9 inhibition), led to significant increase in affinity and selectivity. Several evolved variants were obtained. The crystal structures of the two final generation <scene name='3gkl/Al/3'>variants</scene> <span style="color:lime;background-color:black;font-weight:bold;">R12-2</span> ('''3gkl'''; T20A, N24D, T27A, S28T, V34D, V37J, E41G, and K57E) and <font color='darkred'><b>R12-13</b></font> ([[3gjn]]; N24D, D25E, T27A, S28T, V34D, V37J, and Y55W) in complex with ColE7 were solved. | Iterative rounds of random mutagenesis and selection of <span style="color:yellow;background-color:black;font-weight:bold;">immunity protein 9 (colored yellow)</span> toward higher affinity for ColE7, and selectivity (against ColE9 inhibition), led to significant increase in affinity and selectivity. Several evolved variants were obtained. The crystal structures of the two final generation <scene name='3gkl/Al/3'>variants</scene> <span style="color:lime;background-color:black;font-weight:bold;">R12-2</span> ('''3gkl'''; T20A, N24D, T27A, S28T, V34D, V37J, E41G, and K57E) and <font color='darkred'><b>R12-13</b></font> ([[3gjn]]; N24D, D25E, T27A, S28T, V34D, V37J, and Y55W) in complex with ColE7 were solved. | ||
Revision as of 11:03, 27 August 2013
|
Contents |
3D structure of Colicin immunity protein
Updated on 27-August-2013
Colicin-D immunity protein
1tfk, 1tfo, 1v74 - EcCIPD + EcColD catalytic domain
Colicin-E2 immunity protein
2no8 – EcCIPE2 – NMR
2wpt – EcCIPE2 + EcColE9 (mutant)
3u43 - EcCIPE2 + EcColE2 DNase domain
Colicin-E3 immunity protein
3eip – EcCIPE3
1jch – EcCIPE3 + EcColE3
2b5u – EcCIPE3 + EcColE3 (mutant)
1e44 – EcCIPE3 + EcColE3 nuclease domain
Colicin-E5 immunity protein
2dfx – EcCIPE5 + EcColE5 C-terminal domain
2fhz – EcCIPE5 + EcColE5 residues 74-180
Colicin-E7 immunity protein
1ayi, 1unk, 1cei – EcCIPE7
2k0d - EcCIPE7 - NMR
1mz8, 7cei – EcCIPE7 + EcColE7 nuclease domain
2jaz, 2jb0, 2jbg, 1znv – EcCIPE7 + EcColE7 nuclease domain (mutant)
2erh, 1ujz – EcCIPE7 (mutant) + EcColE7 (mutant)
4f37 – EcCIPE7 + IM7 immunity protein + antibody peptide
Colicin-E8 immunity protein
Colicin-E9 immunity protein
1e0h, 1imp, 1imq – EcCIPE9 - NMR
2k5x, 1emv, 1bxi – EcCIPE9 + EcColE9 DNase domain
2vln, 2vlo, 2vlp, 2vlq - EcCIPE9 + EcColE9 DNase domain (mutant)
2gze, 2gzg, 2gzi, 2gzj, 2gzf, 2gyk, 1fr2 - EcCIPE9 (mutant) + EcColE9 DNase domain
3gjn – EcCIPE9 (mutant) + EcColE7 nuclease domain
3gkl – EcCIPE9 (mutant) + EcColE7 nuclease domain (mutant)
Colicin-M immunity protein
2xgl, 4aeq – EcCIPM periplasmic domain
Proteopedia Page Contributors and Editors (what is this?)
Michal Harel, Alexander Berchansky, Jaime Prilusky, Gemma McGoldrick